Employees: 700
Size Cytek Biosciences (CTKB) is a United States Health Care company (Medical Specialties) with a market value of $774M, the 2393rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $5.92 on 18 Nov 2026.
Performance Over six months the shares gained 57.0%, against -17.5% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 5.5% over the last twelve months (peer median +12.6%); the operating margin is -21.1% (peer median 12.8%).
Valuation It trades at 2.6× enterprise value to sales against a peer median of 3.4× (8th cheapest of 21).
Capital Return on invested capital runs 45.9 points below its cost of capital (10.6% WACC).
Backlog Backlog (remaining performance obligations) was $49.0M at 30 Sep 2026, up 9% on a year earlier — 0.2 years of trailing revenue. Backlog detail →
Short interest Short interest is 3.1% of the free float (30 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $208M | $201M | $200M | $193M | $164M |
| Revenue growth | — | +1% | +4% | +18% | — |
| Gross profit | $114M | $104M | $111M | $109M | $102M |
| EBITDA | -$31.9M | -$28.4M | -$12.6M | -$17.1M | $4.50M |
| Net income | -$81.2M | -$66.5M | -$6.02M | -$12.1M | $2.58M |
| Free cash flow | -$13.5M | -$8.77M | $21.9M | $633,000 | -$22.0M |
| Capital expenditure | $7.03M | $4.19M | $3.73M | $4.83M | $9.87M |
| Total debt | $33.0M | $33.0M | $27.8M | $33.2M | $35.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CTKB | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.9% | -8.5% | highest of 21 |
| 6-month return | +57.0% | -17.5% | 3rd highest of 21 |
| Distance from 52-week high | -6.5% | -41.0% | 4th highest of 21 |
| Revenue growth (TTM) | +5.5% | +12.6% | 8th lowest of 21 |
| Operating margin | -21.1% | 12.8% | 3rd lowest of 21 |
| EV / Sales | 2.6× | 3.4× | 8th cheapest of 21 |
| ROIC minus cost of capital | -45.9 pp | -0.3 pp | 2nd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cytek Biosciences CTKB | United States | $774M | +57% | +6% | -21% | 2.6× | n/a | n/a |
| Mesa Laboratories MLAB | United States | $775M | +33% | +2% | 10% | 3.6× | 21.3% | +13.2% |
| LifeTech Scientific 1302.HK | Hong Kong | $771M | -30% | +1% | 12% | 3.2× | 9.6% | +15.5% |
| Varex Imaging VREX | United States | $771M | +79% | +5% | 8% | 1.2× | n/a | n/a |
| Beta Bionics BBNX | United States | $779M | +42% | +44% | -73% | 4.3× | n/a | n/a |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $768M | -16% | +39% | 25% | 3.6× | 3.8% | +105.8% |
| Standard Engineering Technology SETL.NS | India | $783M | +168% | +45% | 14% | 7.7× | n/a | n/a |
| Maccura Biotechnology 300463.SZ | China | $756M | -18% | -1% | -4% | 2.3× | 7.9% | -10.2% |
| Sino Medical Sciences Technology 688108.SS | China | $753M | -41% | +22% | 19% | 7.8× | 27.9% | +9.9% |
| Allmed Medical Products 002950.SZ | China | $747M | -32% | +14% | 8% | 1.5× | n/a | n/a |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $744M | -3% | +12% | 18% | 2.8× | -1.9% | +11.8% |
| Shanghai Runda Medical Technology 603108.SS | China | $744M | -36% | -12% | -2% | 1.7× | 20.3% | -0.2% |
| Seegene 096530.KS | South Korea | $808M | -26% | +13% | 13% | 1.2× | -6.7% | -15.9% |
| InMode INMD | United States | $741M | -8% | +2% | 18% | 0.6× | -10.8% | +12.4% |
| Advanced Medical Solutions AMS.L | United Kingdom | $811M | +27% | +6% | 12% | 3.0× | 20.0% | +21.4% |
| MedCap MCAP.ST | Sweden | $811M | -4% | +17% | 15% | 3.6× | 2.7% | +20.9% |
| Beijing Aerospace Changfeng 600855.SS | China | $738M | -44% | -10% | -19% | 4.5× | n/a | n/a |
| BMC Medical 301367.SZ | China | $737M | -17% | +37% | 17% | 1.8× | -1.5% | +15.6% |
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $736M | -37% | +39% | 24% | 5.8× | 17.1% | +24.2% |
| Beijing Hotgen Biotech 688068.SS | China | $815M | -37% | +8% | -94% | 9.6× | n/a | n/a |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $818M | -36% | +36% | 16% | 6.8× | 35.6% | +17.1% |
Cytek Biosciences reported $49.0M of remaining performance obligations at 30 Sep 2026, up 9% from a year earlier and up 4% from the previous quarter. That is 0.2 years of trailing revenue already under contract. Book-to-bill last quarter: 1.03.